Clinical Trial Update: ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update for ARQ 197 in relapsed or refractory germ cell tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cns Germ Cell Tumors

Drugs mentioned

• ARQ 197 (tivantinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas) | Phase 2 | Status: TERMINATED | Results posted: 2020-09-09